Supplementary Figure S2 from Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure S2. Study design of JCOG1404/WJOG8214L. Abbreviations: NSCLC, non-small cell lung cancer; EGFR; epidermal growth factor receptor; Exon 19 DEL, EGFR exon 19 deletion; Exon 21 L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology Group; PS, performance status; CNS, central nervous system; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PD, progressive disease.
Authors: Shintaro Kanda, Seiji Niho, Takayasu Kurata, Shogo Nomura, Yosuke Kawashima, Eiji Iwama, Toshihide Yokoyama, Yasutaka Watanabe, Hiroshi Tanaka, Yutaka Fujiwara, Yoshitaka Zenke, Koichi Azuma, Hirokazu Taniguchi, Ryo Toyozawa, Yukio Hosomi, Haruyasu Murakami, Satoshi Hara, Akihiro Bessho, Nobuyuki Yamamoto, Yuichiro Ohe
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4411284085